13.3% DEXTROSE INJECTION, USP 13.3 G / 100 ML
DEXTROSE : 13.3 G / 100 ML · DIN 02015072 · BAXTER CORPORATION CLINTEC NUTRITION DIVISION
Health Canada status: CANCELLED POST MARKET
What is 13.3% DEXTROSE INJECTION, USP?
13.3% DEXTROSE INJECTION, USP 13.3 G / 100 ML contains DEXTROSE : 13.3 G / 100 ML. It is listed in the Health Canada Drug Product Database under DIN 02015072, held by BAXTER CORPORATION CLINTEC NUTRITION DIVISION, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 05-Aug-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02015072 |
|---|---|
| Brand name | 13.3% DEXTROSE INJECTION, USP |
| Generic / active ingredient | DEXTROSE : 13.3 G / 100 ML |
| Manufacturer | BAXTER CORPORATION CLINTEC NUTRITION DIVISION |
| Strength | 13.3 G / 100 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Ethical |
| ATC code | B05BA03 CARBOHYDRATES |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Aug-2015 |
| Original market date | 1992-12-31 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code B05BA03 CARBOHYDRATES. 9 of 32 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| 10% DEXTROSE INJECTION USP | 100 MG | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01924427 |
| 10% DEXTROSE INJECTION, USP | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060364 |
| 5% DEXTROSE INJECTION | 50 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02403536 |
| 5% DEXTROSE INJECTION USP | 50 MG | SOLUTION | B. BRAUN MEDICAL INC | MARKETED | DIN 01924281 |
| 5% DEXTROSE INJECTION, USP | 5 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 00060348 |
| 70% DEXTROSE INJECTION USP | 70 G / 100 ML | SOLUTION | BAXTER CORPORATION | MARKETED | DIN 02014874 |
| DEXTROSE INJECTION | 50 % | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02517132 |
| DEXTROSE INJECTION USP | 50 MG | SOLUTION | ICU MEDICAL CANADA INC | MARKETED | DIN 00037915 |
| DEXTROSE INJECTION USP | 500 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02468514 |
| 10% DEXTROSE INJECTION, USP | 10 G / 100 ML | SOLUTION | BAXTER CORPORATION CLINTEC NUTRITION DIVISION | CANCELLED POST MARKET | DIN 02014823 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.